Pseudomonas Aeruginosa Phage Lysate As an Immunobiological Agent. 1. Selection of Pseudomonas Aeruginosa Clinical Strains for Phage Lysate Preparation

Overview

Journal Folia Microbiol (Praha)

Publisher Springer

Specialty Microbiology

Date 1999 Sep 18

PMID 10489698

Citations 2

Authors

G SEKANINOVA

M Kolarova

J PILLICH

J Semenka

H Slavikova

D Kubickova

V Zajicova

Affiliations

Soon will be listed here.

Abstract

A total of 2087 Pseudomonas aeruginosa isolates collected during the period 1994-1997 were used as starting material. Out of 1704 in-patient isolates, 299 strains were selected for the preparation of phage lysates but only five strains provided stable lysates, i.e., maintained the ability to be repeatedly and completely lysed by the appropriate phage in the course of several years. A set of 193 out-patients (189) and water sources (4) isolates failed to yield strains suitable for phage lysate preparation; 190 strains isolated abroad from patients with cystic fibrosis or respiratory infections included three isolates which, despite having a high degree of mucus production, were suitable for lysate preparation. The antigenic pattern of the phage lysates was ascertained by SDS-polyacrylamide gel electrophoresis.

Citing Articles

Efficacy of bacteriophage Lysed marker vaccine in laboratory animal models with a novel DIVA for haemorrhagic septicaemia.

Qureshi S, Saxena H Saudi J Biol Sci. 2019; 26(1):141-147.

PMID: 30622418 PMC: 6319188. DOI: 10.1016/j.sjbs.2017.05.001.

Cystic fibrosis therapy: a community ecology perspective.

Conrad D, Haynes M, Salamon P, Rainey P, Youle M, Rohwer F Am J Respir Cell Mol Biol. 2012; 48(2):150-6.

PMID: 23103995 PMC: 3604065. DOI: 10.1165/rcmb.2012-0059PS.

References

May T, Shinabarger D, Maharaj R, Kato J, Chu L, DeVault J . Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev. 1991; 4(2):191-206. PMC: 358191. DOI: 10.1128/CMR.4.2.191. View

Jaeger K, Ransac S, Dijkstra B, Colson C, van Heuvel M, Misset O . Bacterial lipases. FEMS Microbiol Rev. 1994; 15(1):29-63. DOI: 10.1111/j.1574-6976.1994.tb00121.x. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Frasch C . Serogroup and serotype classification of bacterial pathogens. Methods Enzymol. 1994; 235:159-74. DOI: 10.1016/0076-6879(94)35138-4. View

Nishio M, Isobe Y, Hatano H, Ohno S, Okuda K, Ishii N . The genetic effect of engineered vaccine on Pseudomonas aeruginosa infection in mice. Immunogenetics. 1993; 38(4):280-2. DOI: 10.1007/BF00188804. View

Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, Tang H . Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun. 1998; 66(1):43-51. PMC: 107856. DOI: 10.1128/IAI.66.1.43-51.1998. View

Jarvis W, Martone W . Predominant pathogens in hospital infections. J Antimicrob Chemother. 1992; 29 Suppl A:19-24. DOI: 10.1093/jac/29.suppl_a.19. View

Neu H . The crisis in antibiotic resistance. Science. 1992; 257(5073):1064-73. DOI: 10.1126/science.257.5073.1064. View

Bergogne-Berezin E, Decre D, Joly-Guillou M . Opportunistic nosocomial multiply resistant bacterial infections--their treatment and prevention. J Antimicrob Chemother. 1993; 32 Suppl A:39-47. DOI: 10.1093/jac/32.suppl_a.39. View

10.

Cryz Jr S, Sadoff J, Furer E . Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb Pathog. 1989; 6(1):75-80. DOI: 10.1016/0882-4010(89)90010-7. View

11.

Shooter R, Walker K, Williams V, Horgan G, PARKER M, ASHESHOV E . Faecal carriage of Pseudomonas aeruginosa in hospital patients. Possible spread from patient to patient. Lancet. 1966; 2(7477):1331-4. DOI: 10.1016/s0140-6736(66)92082-4. View

12.

PILLICH J, Kubickova D, VYMOLA F . Phage plaques and autoplaques in Pseudomonas aeruginosa strains. J Hyg Epidemiol Microbiol Immunol. 1985; 29(2):163-7. View

13.

Toth A, Schodel F, Duchene M, Massarrat K, Blum B, Schmitt A . Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin. Vaccine. 1994; 12(13):1215-21. DOI: 10.1016/0264-410x(94)90246-1. View

14.

Miler J, Spilsbury J, Jones R, Roe E, Lowbury E . A new polyvalent Pseudomonas vaccine. J Med Microbiol. 1977; 10(1):19-27. DOI: 10.1099/00222615-10-1-19. View

15.

Pennington J . Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis. 1979; 140(1):73-80. DOI: 10.1093/infdis/140.1.73. View

16.

Fichtenbaum C, Woeltje K, Powderly W . Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis. 1994; 19(3):417-22. DOI: 10.1093/clinids/19.3.417. View

17.

STANISLAVSKY E, Lam J . Pseudomonas aeruginosa antigens as potential vaccines. FEMS Microbiol Rev. 1998; 21(3):243-77. DOI: 10.1111/j.1574-6976.1997.tb00353.x. View

18.

Holder I, Wheeler R, MONTIE T . Flagellar preparations from Pseudomonas aeruginosa: animal protection studies. Infect Immun. 1982; 35(1):276-80. PMC: 351026. DOI: 10.1128/iai.35.1.276-280.1982. View

19.

Stoddart J, Airey I, Bint A . Pseudomonas aeruginosa in the intensive care unit. Intensive Care Med. 1982; 8(6):279-82. DOI: 10.1007/BF01716738. View

20.

SOUREK J, VYMOLA F, ZELENKOVA L . Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine. Zentralbl Bakteriol A. 1980; 246(3):353-62. View